Beranda › Dermatitis Atopik (Eksim) › Pennsylvania
Uji klinis Dermatitis Atopik (Eksim) di Pennsylvania
13 studi untuk Dermatitis Atopik (Eksim) mencari peserta di lokasi di Pennsylvania.
Kota di Pennsylvania
Teks studi resmi (Bahasa Inggris)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- UPMC - Department of Dermatology- Site Number : 8400024, Pittsburgh
Menerima pesertaStudi observasional
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07290803Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Camp Hill
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07298395A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
- Paddington Testing Co, Inc, Philadelphia
- UPMC Department of Dermatology, Pittsburgh
Menerima pesertaFase 2
Usia 18 hingga 64 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07216027A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Pittsburgh
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07003425A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
- Best Skin Research LLC, Camp Hill
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07223697A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Best Skin Research, LLC, Camp Hill
- UPMC Department of Dermatology, Pittsburgh
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07599813FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- Paddington Testing Company, Philadelphia
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT06564389A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Clinical Research of Philadelphia /ID# 264972, Philadelphia
- University of Pittsburgh Medical Center /ID# 264526, Pittsburgh
- Dermatology Associates of Plymouth Meeting /ID# 267286, Plymouth Meeting
Menerima pesertaFase 3
Usia 18 hingga 63 · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT06389136The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
- University of Pittsburgh Medical Center, Pittsburgh
- UPMC Department of Dermatology, Pittsburgh
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Mei 2026 · NCT06928246A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Paddington Testing Co, Inc, Philadelphia
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Mei 2026 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 8559, Philadelphia
- Galderma Investigational Site 7103, Philadelphia
Menerima pesertaStudi observasional
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 13 Mar 2026 · NCT06988605Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- University of Pittsburgh Medical Center, Pittsburgh
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Des 2025 · NCT00177268A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
- DermDox Centers for Dermatology, Camp Hill
- University of Pennsylvania, Philadelphia
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Sep 2025 · NCT06055361Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.